Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects.

Interleukin-8 (IL-8) is a major cytokine in the recruitment of neutrophils (polymorphonuclear leukocytes) to areas of inflammation. It also activates T lymphocytes and cytokine-primed basophils and eosinophils and therefore may be implicated as an effector in allergic inflammation. IL-8 has also been identified as a mediator in such inflammatory pulmonary conditions as cystic fibrosis, allergen challenge, and sarcoidosis. To investigate the bioactivity of IL-8 in humans, we examined the effects of nasal challenge with human recombinant IL-8 in a double-blind placebo-controlled crossover study in which nasal resistance and rhinitic symptoms were monitored for 4 h after challenge. Cellular infiltration was quantified on differentially stained nasal smears obtained at hourly intervals. Cellular responses caused by in vivo priming were assessed by a comparison of atopic and nonatopic patient groups. A significant neutrophilic infiltrate in smear samples was observed in all patients challenged with IL-8 from 12 +/- 4% (mean +/- SEM) at baseline to 60 +/- 6% after 4 h; placebo challenge resulted in an increase in neutrophils to 30 +/- 4% (p < 0.04). Additionally, a significant increase in cumulative eosinophil recruitment occurred over the challenge period. Nasal resistance was significantly increased 10 min after instillation of IL-8 in all subjects compared with placebo, but there was no difference between atopic and nonatopic subjects. Nasal rhinitic symptoms were also increased in all subjects receiving IL-8 compared with placebo. In a further study in 19 subjects, nasal biopsy was performed 3 h after IL-8 or placebo challenge.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  R. Strieter,et al.  Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups , 1993, The Lancet.

[2]  J. Westwick,et al.  Interleukin 8 (IL-8) is Produced by the Bronchoalveolar Lavage Cell Population from Patients with Active but not Inactive Sarcoidosis , 1993 .

[3]  P. Howarth,et al.  Interleukin 4 is localized to and released by human mast cells , 1992, The Journal of experimental medicine.

[4]  K. Togawa,et al.  The effect of recombinant human interleukin-5 on eosinophil accumulation and degranulation in human nasal mucosa. , 1992, The Journal of allergy and clinical immunology.

[5]  S. Mattoli,et al.  Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. , 1992, The Journal of allergy and clinical immunology.

[6]  C. Hawkey,et al.  Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. , 1992, Clinical science.

[7]  T. Standiford,et al.  Pulmonary fibroblast expression of interleukin-8: a model for alveolar macrophage-derived cytokine networking. , 1991, American journal of respiratory cell and molecular biology.

[8]  R. Crystal,et al.  Interleukin-8 gene expression in human bronchial epithelial cells. , 1991, The Journal of biological chemistry.

[9]  J. Westwick,et al.  hrIL‐8‐Induced Hyperresponsiveness in Guinea Pig Perfused Lungs , 1991, Annals of the New York Academy of Sciences.

[10]  L. Koenderman,et al.  Modulation and induction of eosinophil chemotaxis by granulocyte- macrophage colony-stimulating factor and interleukin-3 , 1991 .

[11]  S. Kunkel,et al.  Modulation of leucocyte adhesion molecules, a T‐cell chemotaxin (IL‐8) and a regulatory cytokine (TNF‐α) in allergic contact dermatitis (rhus dermatitis) , 1991, The British journal of dermatology.

[12]  M. Raffeld,et al.  Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1. , 1991, The Journal of investigative dermatology.

[13]  B. Dewald,et al.  Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8 , 1991, The Journal of experimental medicine.

[14]  T. Standiford,et al.  Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. , 1991, Experimental lung research.

[15]  K. Matsushima,et al.  Properties of the novel proinflammatory supergene "intercrine" cytokine family. , 1991, Annual review of immunology.

[16]  M. Baggiolini,et al.  Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils , 1990, The Journal of experimental medicine.

[17]  D. Blanchard,et al.  Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8. , 1990, Journal of immunology.

[18]  E. Leonard,et al.  Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. , 1990, Journal of immunology.

[19]  J. Schifferli,et al.  NAP-1/IL-8 induces up-regulation of CR1 receptors in human neutrophil leukocytes. , 1990, Biochemical and biophysical research communications.

[20]  M. Sticherling,et al.  Detection of neutrophil-activating peptide NAP/IL-8 and NAP/IL-8 mRNA in human recombinant IL-1 alpha- and human recombinant tumor necrosis factor-alpha-stimulated human dermal fibroblasts. An immunocytochemical and fluorescent in situ hybridization study. , 1990, Journal of immunology.

[21]  B. Dewald,et al.  The neutrophil-activating peptide NAF/NAP-1 induces histamine and leukotriene release by interleukin 3-primed basophils , 1989, The Journal of experimental medicine.

[22]  D. Bainton,et al.  GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. , 1989, The Journal of clinical investigation.

[23]  J. Van Damme,et al.  Granulocyte chemotactic protein/interleukin-8 induces plasma leakage and neutrophil accumulation in rabbit skin. , 1989, The American journal of pathology.

[24]  B. Dewald,et al.  In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. , 1989, The American journal of pathology.

[25]  R. Strieter,et al.  Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. , 1989, Science.

[26]  B. Dewald,et al.  Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Appella,et al.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor , 1988, The Journal of experimental medicine.

[28]  E. Appella,et al.  Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Matsushima,et al.  Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). , 1987, Journal of immunology.

[30]  M. Gleeson,et al.  Assessment of nasal airway patency: a comparison of four methods. , 1986, Clinical otolaryngology and allied sciences.

[31]  I. Olsson,et al.  Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein , 1984, Nature.

[32]  M. Baggiolini,et al.  Subcellular Localization and Heterogeneity of Neutral Proteases in Neutrophilic Polymorphonuclear Leukocytes , 1975, The Journal of experimental medicine.